Session 1: From a patient's point of view

O1.1

The Minimally Important Difference for the Xerostomia Inventory among Sjögren’s Disease Patients

O1.2

Novel Tool ‘The Sjögren's Symptoms Card and my Positive Health Spider Web”

Session 2: Glands and imaging

O2.1

Stratifying Salivary Gland Secretory Hypofunction of Sjögren’s Syndrome Based on A Novel Ultrasonographic Scoring Model

O2.2

Development of salivary gland organoids to study Sjögren’s disease

O2.3

Harmonization of digital image analysis of salivary gland histological parameters in Sjögren’s disease

O2.4

Ultra-high frequency ultrasound examination of labial salivary glands and lachrymal glands: diagnostic accuracy and prognostic value

Session 3: Pathogenetic aspects I

O3.1

Labial salivary gland CD4+ T-cell composition in Sjögren’s Disease is heterogeneous and contains multiple cell differentiation states

O3.2

IL-27 drives CD4 and CD8 T cell differentiation in lacrimal gland autoimmunity

O3.3

Transcriptomic profiling of Sjogren’s salivary glands identifies rheumatoid factor signatures associated with both follicular and extra-follicular responses

O3.4

Rare deleterious variants in NFAT5 and PRKCD in three siblings with pediatric-onset Sjögren’s disease

O3.5

TYK2 is required for salivary and lacrimal gland inflammation in a mouse model of Sjogren's disease

O3.6

Amlexanox inhibits type I interferon production and suppresses B cell differentiation in vitro: a potential novel therapeutic option for Sjögren's syndrome and other systemic inflammatory diseases

O3.7

Single-cell RNA-sequencing of PBMCs confirms the central role of anti-SSA antibodies and its association with Interferon-stimulated genes in the systemic expression of Sjögren’s disease

O3.8

Lysosome-associated membrane protein 3 amplifies type I IFN response by inducing ectopic TLR7 expression in salivary gland epithelial cells

Session 4: Trials and tools

O4.1

Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Disease having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

O4.2

Iscalimab (CFZ533) in patients with Sjögren’s Disease: Week 24 efficacy and biomarker results of a randomized, placebo-controlled, phase 2b dose-ranging study

O4.3

Clinical efficacy and patient-reported outcomes (PROs) in anti-Ro/Sjögren’s syndrome–related antigen A (SSA) antibody–positive patients with active systemic lupus erythematosus (SLE) treated with deucravacitinib in the phase 2 PAISLEY trial

O4.4

Large-scale discovery proteomics in Sjögren's disease: delineating treatment response and pathophysiological insights from the RepurpSS-I trial

Session 5: Extra-glandular involvement

O5.1

The burden and characteristics of neurological symptoms in patients with Sjögren disease

O5.2

Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations

O5.3

Sleep disturbance, Depression and Fatigue in Sjogren's disease: the impact on occupational health

O5.4

Real-World fatigue variability in Sjögren’s Syndrome

Session 6: Pathogenic aspects II

O6.1

Cytoplasmic accumulation of mitochondrial dsRNAs by aberrant SUV3 expression activates PKR in monocytes of childhood Sjögren’s disease

O6.2

Transcriptional dysregulation in Sjögren’s disease through the lens of mitophagy

O6.3

Harnessing cell energy metabolism to suppress salivary gland inflammation in Sjogren Syndrome: role of glycolysis in metabolic reprogramming and regulation of epithelial cell inflammation

O6.4

Differentiation of human pluripotent stem cells (iPSCs) into human salivary gland epithelial progenitors

Session 7: Outstanding abstracts presentations

O7.1

Sexual experience and functioning in female and male patients with primary Sjögren’s Disease: a qualitative study

O7.2

Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

O7.3

Stratification of Sjögren’s disease, based on symptoms, clinical and routine biological data, is supported by distinct pathophysiological pathway

O7.4

cGAS-STING pathway activation drive Type-I IFN in Sjögren’s Disease

Session 8: Classification and stratification

O8.1

Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Sjögren’s cases in the Sjögren’s Genetic Network (SGENE) demonstrates divergent genetic architecture in patient subphenotypes

O8.2

The weight of immunoblot testing in Sjögren’s Syndrome: does the quantitative titer of autoantibodies influence the severity of disease onset?

O8.3

Damage accrual in Sjögren’s disease over 5 years: the GIRRCS Sjogren’s disease cohort experience.

O8.4

Mucosal associated lymphoid tissue lymphoma predictors in primary Sjogren’s Disease by data driven analysis in harmonized patients.

Session 9: Looking foward!

O9.1

Ultrasound guided core-needle biopsy of the unswollen parotid gland is a reliable technique in the work-up of primary Sjögrens’ syndrome

O9.2

Diagnosing Sjogren's Syndrome: A Multi-modal Deep Learning Approach with Histopathologic Images and Clinical Data

O9.3

A high polygenic risk score is associated with SSA antibody positivity in primary Sjögren’s syndrome

O9.4

Deconstruction and Reconstruction of Sjögren’s Disease:  AMP-AIM Partnership